YIH
TRVI icon

Y-Intercept (HK)’s Trevi Therapeutics TRVI Stock Holding History

Y-Intercept (HK)’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-86,830
Closed -$475K – 2057
2025
Q2 		$475K Buy
+86,830
New +$540K 0.01% 1224

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Y-Intercept (HK)'s TRVI Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Trevi Therapeutics (TRVI) in Q3 2025, closing a stake of 86,830 shares — an estimated $475K sold.

Y-Intercept (HK) first reported a position in TRVI in Q2 2025 and held it in 1 quarter. The position peaked at $475K in Q2 2025. 164 funds tracked by Wall St. Rank hold TRVI as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Trevi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 86,830 Trevi Therapeutics shares in Q3 2025, an estimated $475K.
  • Y-Intercept (HK) first reported a position in Trevi Therapeutics in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Trevi Therapeutics position peaked at $475K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.